Eagle Pharmaceuticals, Inc. (EGRX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 188 | 172 | 317 | - | - | - | 258 | - |
| Operating profit | $m | 81 | 24 | ||||||
| Net profit | $m | 12 | -9 | 36 | - | - | - | 16 | - |
| EPS reported | $ | 2.73 | 1.18 | ||||||
| Operating cashflow per share | $ | 3.92 | 2.38 | ||||||
| Capex per share | $ | 0.01 | 0.00 | ||||||
| FCF per share | $ | 3.91 | 2.38 | ||||||
| Free cash flow | $m | 51 | -9 | ||||||
| Net debt | $m | 7 | 55 | ||||||
| Book value equity | $m | 234 | 252 | ||||||
| Book value per share | $ | 17.88 | 19.16 | ||||||
| Number of shares | m | 13.07 | 13.15 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 10.71 | 0.86 | ||||||
| P/B LTM | x | 1.62 | 0.01 | ||||||
| P/S LTM | x | 1.19 | 0.01 | ||||||
| P/FCF LTM | x | 7.48 | 0.07 | ||||||
| EV/EBITDA LTM | x | 5.04 | 0.19 | ||||||
| EV/Sales LTM | x | 1.23 | 0.05 | ||||||
| Earnings Yield LTM | % | +9.34% | +116.28% | ||||||
| FCF Yield | % | +13.36% | -446.13% | ||||||
| Quality | |||||||||
| ROE | % | +15.26% | +17.39% | ||||||
| ROIC | % | +15.51% | +15.51% | ||||||
| Operating margin | % | +25.57% | +25.57% | ||||||
| Gross margin | % | +70.01% | +70.01% | ||||||
| FCF/Sales | % | +15.96% | +9.73% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +84.56% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +81.11% | - | ||||||
| Operating Profit Growth | % | +2823.8% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.75 | -0.13 | ||||||
| Net Debt/EBITDA | x | 0.16 | 0.16 | ||||||
| EBIT/Net interest | x | 20.01 | 20.01 | ||||||
| Net debt/market cap | % | +16.52% | +29.67% | ||||||
| Net debt/Equity | x | 0.03 | 0.22 | ||||||
| Gross debt/equity | x | 0.29 | 0.28 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free